


Claims

We claim:

1. A compound of formula (I):



(I)

wherein:

A is selected from H; Ht;  $-\text{R}^1\text{-Ht}$ ;  $-\text{R}^1\text{-C}_1\text{-C}_6$  alkyl, which is optionally substituted with one or more groups independently selected from hydroxy,  $\text{C}_1\text{-C}_4$  alkoxy, Ht,  $-\text{O-Ht}$ ,  $-\text{NR}^2\text{-CO-N(R}^2)_2$  or  $-\text{CO-N(R}^2)_2$ ;  $-\text{R}^1\text{-C}_2\text{-C}_6$  alkenyl, which is optionally substituted with one or more groups independently selected from hydroxy,  $\text{C}_1\text{-C}_4$  alkoxy, Ht,  $-\text{O-Ht}$ ,  $-\text{NR}^2\text{-CO-N(R}^2)_2$  or  $-\text{CO-N(R}^2)_2$ ; or  $\text{R}^7$ ;

each  $\text{R}^1$  is independently selected from  $-\text{C(O)-}$ ,  $-\text{S(O)}_2-$ ,  $-\text{C(O)-C(O)-}$ ,  $-\text{O-C(O)-}$ ,  $-\text{O-S(O)}_2-$ ,  $-\text{NR}^2\text{-S(O)}_2-$ ,  $-\text{NR}^2\text{-C(O)-}$  or  $-\text{NR}^2\text{-C(O)-C(O)-}$ ;

each Ht is independently selected from  $\text{C}_3\text{-C}_7$  cycloalkyl;  $\text{C}_5\text{-C}_7$  cycloalkenyl;  $\text{C}_6\text{-C}_{10}$  aryl; or a 5-7 membered saturated or unsaturated heterocycle, containing one or more heteroatoms selected from N,  $\text{N(R}^2)$ , O, S and  $\text{S(O)}_n$ ; wherein said aryl or said heterocycle is optionally fused to Q; and wherein any member of said Ht is optionally substituted with one or more substituents independently selected from oxo,  $-\text{OR}^2$ ,  $\text{SR}^2$ ,  $-\text{R}^2$ ,  $-\text{N(R}^2)(\text{R}^2)$ ,  $-\text{R}^2\text{-OH}$ ,  $-\text{CN}$ ,  $-\text{CO}_2\text{R}^2$ ,  $-\text{C(O)-N(R}^2)_2$ ,  $-\text{S(O)}_2\text{-N(R}^2)_2$ ,  $-\text{N(R}^2)\text{-C(O)-R}^2$ ,  $-\text{C(O)-R}^2$ ,  $-\text{S(O)}_n\text{-R}^2$ ,  $-\text{OCF}_3$ ,  $-\text{S(O)}_n\text{-Q}$ , methylenedioxy,  $-\text{N(R}^2)\text{-S(O)}_2(\text{R}^2)$ , halo,  $-\text{CF}_3$ ,  $-\text{NO}_2$ , Q,  $-\text{OQ}$ ,  $-\text{OR}^7$ ,  $-\text{SR}^7$ ,  $-\text{R}^7$ ,  $-\text{N(R}^2)(\text{R}^7)$  or  $-\text{N(R}^7)_2$ ;

each  $R^1$  is independently selected from H, Ht or  $C_1-C_6$  alkyl optionally substituted with Q or  $R^{1c}$ ;

B, when present, is  $-N(R^2)-C(R^3)_2-C(O)-$ ;

each x is independently 0 or 1;

5 each  $R^3$  is independently selected from H, Ht,  $C_1-C_6$

alkyl,  $C_2-C_6$  alkenyl,  $C_3-C_6$  cycloalkyl or  $C_5-C_6$  cycloalkenyl;

wherein any member of said  $R^3$ , except H, is optionally substituted with one or more substituents selected from

$-OR^2$ ,  $-C(O)-NH-R^2$ ,  $-S(O)_n-N(R^2)(R^2)$ , Ht,

10  $-CN$ ,  $-SR^2$ ,  $-CO_2R^2$ ,  $NR^2-C(O)-R^2$ ;

each n is independently 1 or 2;

G, when present, is selected from H,  $R^7$  or  $C_1-C_4$  alkyl, or, when G is  $C_1-C_4$  alkyl, G and  $R^7$  are bound to one another either directly or through a  $C_1-C_3$  linker to form a

15 heterocyclic ring; or

when G is not present, the nitrogen to which G is attached is bound directly to the  $R^7$  group in  $-OR^7$  with the concomitant displacement of one -ZM group from  $R^7$ ;

D is selected from Q;  $C_1-C_6$  alkyl or  $C_2-C_4$  alkenyl, 20 which is optionally substituted with one or more groups selected from  $C_3-C_6$  cycloalkyl,  $-OR^2$ ,  $-S-Ht$ ,  $-R^3$ ,  $-O-Q$  or Q;  $C_3-C_6$  cycloalkyl or  $C_5-C_6$  cycloalkenyl, which is optionally substituted with or fused to Q;

each Q is independently selected from a 3-7 25 membered saturated, partially saturated or unsaturated carbocyclic ring system; or a 5-7 membered saturated, partially saturated or unsaturated heterocyclic ring containing one or more heteroatoms selected from O, N, S,  $S(O)_n$  or  $N(R^2)$ ; wherein Q is optionally substituted with one 30 or more groups selected from oxo,  $-OR^2$ ,  $-R^2$ ,  $-N(R^2)_2$ ,  $-N(R^2)-C(O)-R^2$ ,  $-R^2-OH$ ,  $-CN$ ,  $-CO_2R^2$ ,  $-C(O)-N(R^2)_2$ , halo or  $-CF_3$ ;


$D'$  is selected from  $-OR^{10}$ ,  $-N=R^{10}$  or  $-N(R^{10})-R^1-R^3$ ;

E is selected from Ht; O-Ht; Ht-Ht;  $-O-R^3$ ;

-N(R<sup>2</sup>)(R<sup>3</sup>); C<sub>1</sub>-C<sub>6</sub> alkyl, which is optionally substituted with one or more groups selected from R<sup>i</sup> or Ht; C<sub>1</sub>-C<sub>6</sub> alkenyl, which is optionally substituted with one or more groups selected from R<sup>i</sup> or Ht; C<sub>3</sub>-C<sub>6</sub> saturated carbocycle, which is optionally substituted with one or more groups selected from R<sup>i</sup> or Ht; or C<sub>1</sub>-C<sub>6</sub> unsaturated carbocycle, which is optionally substituted with one or more groups selected from R<sup>i</sup> or Ht;

each R<sup>i</sup> is independently selected from -OR<sup>i</sup>, -SR<sup>i</sup>, -C(O)-NHR<sup>i</sup>, -S(O)<sub>2</sub>-NHR<sup>i</sup>, halo, -NR<sup>i</sup>-C(O)-R<sup>i</sup>, -N(R<sup>i</sup>)<sub>2</sub> or -CN;

each R<sup>-</sup> is independently selected from hydrogen,



wherein each M is independently selected from H, Li, Na, K, Mg, Ca, Ba, -N(R<sup>i</sup>)<sub>4</sub>, C<sub>1</sub>-C<sub>12</sub>-alkyl, C<sub>1</sub>-C<sub>12</sub>-alkenyl, or -R<sup>e</sup>; wherein 1 to 4 -CH<sub>2</sub> radicals of the alkyl or alkenyl group, other than the -CH<sub>2</sub> that is bound to Z, is optionally replaced by a heteroatom group selected from O, S, S(O), S(O<sub>2</sub>), or N(R<sup>2</sup>); and wherein any hydrogen in said alkyl, alkenyl or R<sup>e</sup> is optionally replaced with a substituent selected from oxo, -OR<sup>2</sup>, -R<sup>2</sup>, N(R<sup>i</sup>)<sub>2</sub>, N(R<sup>i</sup>)<sub>3</sub>, R<sup>i</sup>-OH, -CN, -CO<sub>2</sub>R<sup>2</sup>, -C(O)-N(R<sup>2</sup>)<sub>2</sub>, S(O)<sub>2</sub>-N(R<sup>2</sup>)<sub>2</sub>, N(R<sup>i</sup>)-C(O)-R<sub>2</sub>, C(O)R<sup>i</sup>, -S(O)<sub>2</sub>-R<sup>i</sup>, OCF<sub>3</sub>, -S(O)<sub>2</sub>-R<sup>e</sup>, N(R<sup>i</sup>)-S(O)<sub>2</sub>(R<sup>i</sup>), halo, -CF<sub>3</sub>, or -NO<sub>2</sub>;

M' is H, C<sub>1</sub>-C<sub>12</sub>-alkyl, C<sub>1</sub>-C<sub>12</sub>-alkenyl, or -R<sup>e</sup>; wherein 1 to 4 -CH<sub>2</sub> radicals of the alkyl or alkenyl group is optionally replaced by a heteroatom group selected from O, S, S(O), S(O<sub>2</sub>), or N(R<sup>i</sup>); and wherein any hydrogen in said alkyl, alkenyl or R<sup>e</sup> is optionally replaced with a substituent selected from oxo, -OR<sup>i</sup>, -R<sup>i</sup>, -N(R<sup>i</sup>)<sub>2</sub>, N(R<sup>i</sup>)<sub>3</sub>, -R<sup>i</sup>-OH, -CN, -CO<sub>2</sub>R<sup>i</sup>, -C(O)-N(R<sup>i</sup>)<sub>2</sub>, -S(O)<sub>2</sub>-N(R<sup>i</sup>)<sub>2</sub>,

$-N(R^2)-C(O)-R_2$ ,  $-C(O)R^2$ ,  $-S(O)_n-R^2$ ,  $-OCF_3$ ,  $-S(O)_n-R^6$ ,  
 $-N(R^2)-S(O)_2(R^2)$ , halo,  $-CF_3$ , or  $-NO_2$ ;

Z is O, S,  $N(R^2)_2$ , or, when M is not present, H.

Y is P or S;

5 X is O or S;

$R^9$  is  $C(R^2)_2$ , O or  $N(R^2)$ ; and wherein when Y is S,

Z is not S;

$R^6$  is a 5-6 membered saturated, partially  
saturated or unsaturated carbocyclic or heterocyclic ring  
10 system, or an 8-10 membered saturated, partially saturated  
or unsaturated bicyclic ring system; wherein any of said  
heterocyclic ring systems contains one or more heteroatoms  
selected from O, N, S,  $S(O)_n$  or  $N(R^2)$ ; and wherein any of  
said ring systems optionally contains 1 to 4 substituents  
15 independently selected from OH,  $C_1-C_4$  alkyl,  $O-C_1-C_4$  alkyl or  
 $O-C(O)-C_1-C_4$  alkyl;

$R^8$  is selected from  $C_1-C_8$  alkyl,  $C_3-C_7$  alkyl or  
cyano substituted  $C_2-C_6$  alkenyl; and


$R^{10}$  is selected from  $C_1-C_8$  alkyl,  $C_2-C_6$  alkenyl,  $C_6-C_{14}$   
20 aryl or Ht, wherein  $R^{10}$  optionally contains up to three  
substituents independently selected from  $-R^3$ ,  $-CN$ ,  $-SR^5$ ,  
 $-SOR^5$ ,  $-SO_2R^5$ ,  $-SR-NR^5-C(O)R^6$ ,  $-NR^5-(SO_2)R^5$ ,  $-C(O)N(R^5)_2$ ,  
 $-C(S)N(R^5)_2$ ,  $-S(O)_2N(R^5)_2$ ,  $-C(O)R^6$ ,  $-C(S)R^6$ ,  $-N(R^5)_2$ ,  $-NR^5-$   
 $C(O)R^5$ ,  $-NR^5-C(O)OR^5$ ,  $-NR^5-C(O)N(R^5)_2$ ,  $-NR^5-C(S)R^5$ ,  $-NR^5-$   
25  $C(S)OR^5$ ,  $-NR^5-C(S)N(R^5)_2$ ,  $-NR^5-C[=N(R^5)]-N(R^5)_2$ ,  $-NH-C[=N-NO_2]-$   
 $NH_2$ ,  $-NH-C[=N-NO_2]-OR^5$ ,  $-N(R^8)_2-C(O)R^8$ ,  $-NH-C[=N-NO_2]-NH_2$ ,  $-NH-$   
 $C[=N-NO_2]-OR^5$ ,  $-N(R^8)_2-C(O)R^8$ ,  $-OC(O)R^6$ ,  $-OC(O)N(R^5)_2$ ,  
 $-OC(S)N(R^5)_2$ , wherein any one of the  $-CH_2$  groups of said  
alkyl or alkenyl chains of  $R^{10}$  may be optionally replaced by  
30 O, S, SO,  $SO_2$ ,  $C(O)$  or  $NR^5$ ;


wherein each  $R^5$  is independently selected from  
hydrogen,  $C_1-C_8$  alkyl,  $C_2-C_8$  alkenyl,  $C_2-C_8$  alkynyl or Ht,  
wherein each  $R^5$ , except for hydrogen, is optionally  
substituted with  $-CF_3$ ,  $-PO_3R^3$ , azido or halo;

or a pharmaceutically acceptable derivative thereof.

2. The compound according to claim 1, wherein at least one R<sup>7</sup> is selected from:

5






5  $\text{PO}_3\text{-spermine}$ ,  $\text{PO}_3\text{-(spermidine)}_2$  or  $\text{PO}_3\text{-(meglamine)}_2$ .

3. A compound of formula (II):

10




15.

wherein A, R<sup>7</sup>, D' and E are as defined in claim 1;  
or a pharmaceutically acceptable derivative thereof.

20


4. A compound of formula (III):



25

wherein Ht, x, R<sup>3</sup>, R<sup>7</sup>, D' and E are as defined in claim 1;  
or a pharmaceutically acceptable derivative thereof.

5. A compound of formula (IV):



wherein A, R<sup>3</sup>, R<sup>7</sup>, D' and E are as defined in claim 1;  
or a pharmaceutically acceptable derivative thereof.

6. The compound according to claim 3, wherein:

A is -C(O)Ht;

D' is -O-R<sup>16</sup>;

15 E is C<sub>6</sub>-C<sub>10</sub> aryl optionally substituted with one or more substituents selected from oxo, -OR<sup>2</sup>, SR<sup>2</sup>, -R<sup>2</sup>, -N(R<sup>2</sup>)<sub>2</sub>, -R<sup>2</sup>-OH, -CN, -CO<sub>2</sub>R<sup>2</sup>, -C(O)-N(R<sup>2</sup>)<sub>2</sub>, -S(O)<sub>2</sub>-N(R<sup>2</sup>)<sub>2</sub>, -N(R<sup>2</sup>)-C(O)-R<sup>2</sup>, -C(O)-R<sup>2</sup>, -S(O)<sub>n</sub>-R<sup>2</sup>, -OCF<sub>3</sub>, -S(O)<sub>n</sub>-Q, methylenedioxy, -N(R<sup>2</sup>)-S(O)<sub>2</sub>(R<sup>2</sup>), halo, -CF<sub>3</sub>, -NO<sub>2</sub>, Q, -OQ, -OR<sup>7</sup>, -SR<sup>7</sup>, -R<sup>7</sup>,  
20 -N(R<sup>2</sup>)(R<sup>7</sup>) or -N(R<sup>7</sup>)<sub>2</sub>; or a 5-membered heterocyclic ring containing one S and optionally containing N as an additional heteroatom, wherein said heterocyclic ring is optionally substituted with one to two groups independently selected from -CH<sub>3</sub>, R<sup>4</sup>, or Ht.

25


7. The compound according to claim 3, wherein:

E is a 5-membered heterocyclic ring containing one S and optionally containing N as an additional heteroatom, wherein said heterocyclic ring is optionally substituted  
30 with one to two groups independently selected from -CH<sub>3</sub>, R<sup>4</sup>, or Ht.

8. The compound according to claim 3, wherein:


$R^7$  in  $-OR^7$  group shown in formula II is  $-PO(OM)_2$  or  $C(O)CH_2OCH_2CH_2OCH_2CH_2OCH_3$  and both  $R^7$  in  $-N(R^7)_2$  are H; or  $R^7$  in  $-OR^7$  group shown in formula II is  $C(O)CH_2OCH_2CH_2OCH_3$ , one  $R^7$  in  $-N(R^7)_2$  is  $C(O)CH_2OCH_2CH_2OCH_3$  and the other is H; and  
 5 wherein M is H, Li, Na, K or C<sub>1</sub>-C<sub>4</sub> alkyl.

9. A compound according to claim 1, having formula (V):



wherein A,  $R^7$ ,  $R^{10}$  and E are as defined in claim 1;  
 20 or a pharmaceutically acceptable derivative thereof.

10. A compound of formula (VI):




wherein:

$R^7$  and  $R^{10}$  are as defined in claim 1;




E is C<sub>1</sub>-C<sub>4</sub> aryl, optionally substituted with one or more groups selected from the group consisting of nitro, oxo, alkoxy, amino, hydroxyamino; heterocyclcyl, optionally substituted with one or more groups selected from the group consisting of nitro, oxo, alkoxy, amino, hydroxyamino or N(CO)OCH<sub>3</sub>;  
or a pharmaceutically acceptable derivative thereof.

11. A compound of formula (VII):



wherein A, E, R<sup>7</sup> and R<sup>10</sup> are as defined in claim 1;  
or a pharmaceutically acceptable derivative thereof.

12. A compound of formula (VIII):



wherein A, R<sup>1</sup>, R<sup>3</sup>, R<sup>7</sup> and E are as defined in claim 1;


or a pharmaceutically acceptable salt thereof.

13. A compound selected from:



5

10


15






20



25





5

wherein  $R^{10}$  is selected from isopropyl or cyclopentyl;  $R^{11}$  is  
 10 selected from  $NHR^7$  or  $OR^7$ ;  $x$ ,  $R^7$  and  $G$  are as defined in  
 claim 1; and  $X^-$  is a pharmaceutically acceptable counterion.

14. A compound selected from:

(3R,3aS,6aR)hexahydrofuro[2,3-b]furan-3-yl N-((1S,2R)-  
 15 1-benzyl-3-(cyclopentyloxy)[(3-[2-(dimethylamino)ethyl]  
 aminophenyl)sulfonyl]amino-2-hydroxypropyl)carbamate;

(3S,3aR,6aS)hexahydrofuro[2,3-b]furan-3-yl N-((1S,2R)-  
 1-benzyl-3-(cyclopentyloxy)[(3-[2-(dimethylamino)ethyl]  
 aminophenyl)sulfonyl]amino-2-hydroxypropyl)carbamate;

(3R, 3aS, 6aR) Hexahydrofuro[2,3-b]furan-3-yl-N-((1S, 2R)-1-benzyl-3-(cyclopentyloxy)(2-[(methylsulfonyl)amino]benzimidazol-5-ylsulfonyl)amino-2-hydroxypropyl) carbamate;

(3R, 3aS, 6aR) hexahydrofuro[2,3-b]furan-3-yl N-(1S, 2R)-3-  
5 [[(3-N-methylaminophenyl) sulfonyl] (cyclopentyloxy) amino]-1-benzyl-2-hydroxypropylcarbamate;

1,3-Dioxan-5-yl N-(1S, 2R)-1-benzyl-3-[(cyclopentyloxy)(2-[(methoxycarbonyl)amino]-1H-benzimidazol-5-ylsulfonyl)amino]-2-hydroxypropylcarbamate;

10 (3R, 3aS, 6aR) hexahydrofuro[2,3-b]furan-3-yl N-(1S, 2R)-1-benzyl-2-hydroxy-3-[[ (4-methoxyphenyl) sulfonyl] (tetrahydro-2H-pyran-4-yloxy) amino]propylcarbamate;

(3R, 3aS, 6aR) hexahydrofuro[2,3-b]furan-3-yl N-(1S, 2R)-3-  
15 [[ (3-aminophenyl) sulfonyl] (cyclopentyloxy) amino]-1-benzyl-2-hydroxypropylcarbamate;

(3R, 3aS, 6aR) hexahydrofuro[2,3-b]furan-3-yl N-[(1S, 2R)-1-benzyl-3-((cyclopentyloxy)[3-(2-[methoxy(methyl)amino]-2-oxoethylamino)phenyl]sulfonylamino)-2-hydroxypropyl] carbamate;

20 (3R, 3aS, 6aR) hexahydrofuro[2,3-b]furan-3-yl N-[(1S, 2R)-1-benzyl-4-(cyclopentyloxy)-2-hydroxy-4-(6-quinoxaliny] sulfonyl)butyl] carbamate;

(3R, 3aS, 6aR) hexahydrofuro[2,3-b]furan-3-yl N-[(1S, 2R)-1-benzyl-3-(cyclopentyloxy)[(4-methoxyphenyl) sulfonyl]amino-  
25 2-hydroxypropyl] carbamate;

(3R, 3aS, 6aR) hexahydrofuro[2,3-b]furan-3-yl N-[(1S, 2R)-1-benzyl-3-((cyclopentyloxy)[3-(2-[(methylsulfonyl)amino]ethylamino)phenyl]sulfonylamino)-2-hydroxypropyl] carbamate;

(3R, 3aS, 6aR) hexahydrofuro[2,3-b]furan-3-yl N-(1S, 2R)-3-  
30 [[ (3-N-methylaminophenyl) sulfonyl] (cyclopentyloxy) amino]-1-benzyl-2-hydroxypropylcarbamate, phosphate ester;

(3R, 3aS, 6aR) hexahydrofuro[2,3-b]furan-3-yl N-(1S, 2R)-3-  
[[ (3-aminophenyl) sulfonyl] (cyclopentyloxy) amino]-1-benzyl-2-hydroxypropylcarbamate phosphate ester;

(3R,3aS,6aR) hexahydrofuro [2,3-b]furan-3-yl N-(1S,2R)-3-[[ (4-aminophenyl) sulfonyl] (cyclopentyloxy) amino]-1-benzyl-2-hydroxypropyl carbamate;

(3R,3aS,6aR) hexahydrofuro[2,3-b]furan-3-yl (1S,2R)-1-  
5 benzyl-3-((1-ethylpropoxy) [(4-hydroxyphenyl) sulfonyl] amino)-2-hydroxypropylcarbamate;

(3R,3aS,6aR) hexahydrofuro[2,3-b]furan-3-yl (1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl) (1-ethylpropoxy) amino]-1-benzyl-2-hydroxypropylcarbamate;

10 (3R,3aS,6aR) hexahydrofuro[2,3-b]furan-3-yl N-[(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl) (cyclopentyloxy) amino]-1-benzyl-2-(phosphonooxy)propyl]carbamate;

(3R,3aS,6aR) hexahydrofuro[2,3-b]furan-3-yl (1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl) (cyclohexyloxy) amino]-1-  
15 benzyl-2-hydroxypropylcarbamate;

(3R,3aS,6aR) hexahydrofuro[2,3-b]furan-3-yl 3-[(1,3-benzodioxol-5-ylsulfonyl) (tetrahydro-2H-pyran-4-yloxy) amino]-1-benzyl-2-hydroxypropylcarbamate;

(3R,3aS,6aR) hexahydrofuro[2,3-b]furan-3-yl N-[(1S,2R)-  
20 3-[(1,3-benzodioxol-5-ylsulfonyl) (cyclopentyloxy) amino]-1-benzyl-2-(phosphonooxy)propyl]carbamate;  
or a pharmaceutically acceptable derivative thereof.

15. The compound according to claim 1 wherein  
25 said compound has a molecular weight less than or equal to about 700 g/mol.

16. The compound according to claim 15 wherein  
said compound has a molecular weight less than or equal to  
30 about 600 g/mol.

17. A pharmaceutical composition comprising an effective antiviral amount of a compound according to any one of claims 1-14 or a pharmaceutically acceptable

derivative thereof together with a pharmaceutically acceptable carrier therefore.

18. The pharmaceutical composition according to  
5 claim 17, further comprising an antiviral agent other than a  
compound according to claims 1-14.

19. A pharmaceutical composition according to  
claim 17 or 18 in the form of a tablet or capsule.  
10

20. A method of treating a virus infection in a  
human comprising administering to said human an effective  
antiviral treatment amount of a compound according to any  
one of claims 1-13 or a pharmaceutically acceptable  
15 derivative thereof.

21. The method according to claim 20 wherein the  
virus infection is an HIV infection.

22. The method according to claim 20 or 21  
20 wherein said step of administering comprises oral  
administration or administration by injection.

23. Use of a compound according to any of claims  
25 1-14 for the manufacture of a medicament for the treatment  
or prophylaxis of a viral infection.

24. Use of a compound according to any of claims  
1-14 or a formulation according to claim 17 for use in  
30 medical therapy.